RxDoctor Payments Data

Kevin Frank, MD

Family Medicine · Lancaster, OHNPI 1689677874

Payments from drug & device makers

$4,884in general payments, 2019–2025

Across 318 payments — averaging $15.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$968
  • Lilly USA, LLC$519
  • AstraZeneca$426
  • Axsome Therapeutics, Inc.$360
  • Amgen$249
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$213
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,868100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,884 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$60,630
Medicare patients
165
Services billed
1,533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$170,561
OzempicSemaglutide57$78,046
FarxigaDapagliflozin Propanediol38$51,063
JanuviaSitagliptin Phosphate26$31,572
RybelsusSemaglutide18$29,423
MyrbetriqMirabegron24$26,666
MounjaroTirzepatide18$25,757
TrulicityDulaglutide22$24,603
Repatha SureclickEvolocumab31$23,318
LinzessLinaclotide11$17,389
EliquisApixaban18$13,626
Vilazodone Hcl39$6,404
Atorvastatin Calcium528$5,087
Fluticasone-SalmeterolFluticasone Propion/Salmeterol13$4,469
Duloxetine Hcl82$3,356

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$89$170,561128 claims
Novo NordiskOzempic, Rybelsus$160$107,46975 claims
AstraZenecaFarxiga$426$51,06338 claims
Lilly USA, LLCMounjaro, Trulicity$519$50,36040 claims
MerckJanuvia$201$31,57226 claims
Astellas Pharma US IncMyrbetriq$110$26,66624 claims
AbbVieLinzess, Synthroid$968$18,88736 claims
PfizerEliquis$141$13,62618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Lancaster

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →